Observational studyCalcified tissue international2016
Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
Observational study in Calcified tissue international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Osteoanabolic Agents in Type 2 Diabetes Mellitus: a Meta-analysis and Review of the Literature.Current osteoporosis reports · 2025Pooled it
- Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis.Journal of bone and mineral metabolism · 2025Trial
- Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.BMC musculoskeletal disorders · 2022Trial
- Teriparatide reduces spinal neuroinflammatory phenotypes in ovariectomized rats revealed by an artificial intelligence-driven glial cell morphometry of bright-field tissue sections.Microscopy (Oxford, England) · 2026Article
- PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice.Bone research · 2026Article
- Early modification of blood glucose levels during teriparatide treatment in postmenopausal women with severe osteoporosis.Journal of endocrinological investigation · 2025Article
- Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective.JBMR plus · 2024Article
- The Risk of Developing Osteosarcoma After Teriparatide Use: A Systematic Review.Orthopedic research and reviews · 2023Review
- Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience.International journal of endocrinology · 2023Article
- Impact of teriparatide therapy in Indian postmenopausal women with osteoporosis with regard to DXA-derived parameters.Therapeutic advances in endocrinology and metabolism · 2022Article
- The Effect of Teriparatide on the Hip: A Literature Review.Hip & pelvis · 2021Review
- Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups.Journal of clinical medicine · 2021Review
- The Pathophysiology of Osteoporosis after Spinal Cord Injury.International journal of molecular sciences · 2021Review
- Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
- A Phase IV Study of the Safety and Efficacy of CinnoParJournal of osteoporosis · 2021Article
- Factors associated with self-rated health in a Norwegian population of older people participating in a preventive home visit program: a cross-sectional study.BMC geriatrics · 2020Article
- Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide.The Journal of international medical research · 2020Observational
- Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study.BMC musculoskeletal disorders · 2020Article
- Effects of anti-osteoporosis medications on radiological and clinical results after acute osteoporotic spinal fractures: a retrospective analysis of prospectively designed study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Article
- Associations of Health-Related Quality of Life, Fear of Falling and Objective Measures of Physical Function with Bone Health in Postmenopausal Women with Low Bone Mass.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(®) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the >18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.